SYDNEY, AUSTRALIA--(Marketwired - Sep 30, 2013) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", the "Company") announced that management will deliver a presentation of the CAN-003 trial data via webcast and teleconference on Wednesday, October 2, 2013 at 8:00 a.m. (Sydney local time). This corresponds to Tuesday, October 1, 2013 at 6:00 p.m. U.S. Eastern daylight time.

The conference call dial-in numbers are as follows:

Australia Toll Free 1 800 838 758
Australia Alternate Toll Free 1 800 131 617
Canada/USA 1 855 237 2970
Germany 0800 189 9369

The call will also be audio webcast with additional supplemental slides available via Before launching the webcast, it is recommended to click on the link and then on "test your systems configuration."

A replay and a transcript of the teleconference will be available through Prima's website following the live event.

CAN-003 is a phase 2 trial of CVac™ for treatment of epithelial ovarian cancer patients in first or second remission. The Company reported top-line analysis of the CAN-003 trial on September 18, 2013. As previously advised, Dr. Jeffrey Goh, one of the lead investigators for CAN-003, will present trial results at the Gynecological Cancer Session of the European Cancer Congress today, October 1, at approximately 8:45am local time in Amsterdam.

About Prima BioMed

Prima BioMed is a globally active leader in the development of personalized bio-therapeutic products for cancer. Prima is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Prima's lead product is CVac™, an autologous dendritic cell-based product currently in clinical trials for ovarian cancer patients in remission and soon starting in trials of other cancer types.

Contact Information:

For further information please contact:

USA Investor/Media:
Ms. Jessica Brown
Prima BioMed Ltd.
+1 (919) 710-9061

Australia Investor/Media:
Mr. James Moses
Mandate Corporate
+61 (0) 420 991 574

Europe Investor/Media:
Mr. Axel Mühlhaus
edicto GmbH
+49 (0) 69 905505-52